MHMichiel Theodorus Hendricus Maria Henkens

Michiel Theodorus Hendricus Maria Henkens

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michiel Theodorus Hendricus Maria Henkens has a total of 241 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The clinical relevance of regional lymph node microarchitecture in oesophageal cancer patients – Results from the UK MRC OE02 trial

    by Maximilian Kloft, Elzbieta Budginaite, Henry C. Woodruff, Gayatri Raghuram, Michiel Henkens, Derek R. Magee, Thorsten O. Goetze, Salah-Eddin Al-Batran, Matthew G. Nankivell, David Cunningham, et al.

  • Open Access

    The clinical relevance of regional lymph node microarchitecture in oesophageal cancer patients – results from the UK MRC OE02 trial

    by Maximilian Kloft, Elzbieta Budginaite, Henry C. Woodruff, Gayatri Raghuram, Michiel Henkens, Derek R. Magee, Thorsten Goetze, Salah-Eddin Al-Batran, Matthew Nankivell, William Allum, et al.

    BackgroundIn oesophageal cancer (OeC) patients, neoadjuvant chemotherapy followed by surgery improves survival. Anti-tumour immune responses are mediated by lymph node (LN) microarchitecture. We investigated whether neoadjuvant chemotherapy and/or presence of tumour changes LN microarchitecture, and whether such changes are associated with survival. MethodsMicroarchitectural features (lymphocytes, germinal centres (GermC), histiocytes) were quantified morphometrically in 433 LNs from 333 OE02 trial patients (165 neoadjuvant chemotherapy+surgery (CS), 168 surgery alone (S)). Features were compared between tumour-negative (LNneg) and tumour-positive LN (LNpos) by treatment group. Associations with clinicopathological variables and overall survival (OS) were evaluated. ResultsLNneg GermC density was lower in CS patients than in S patients (median: 1% vs 2%; p=0.0004). No other microarchitectural features differed by treatment group or LN status (LNneg vs LNpos). Low histiocyte content in LNneg and LNpos was associated with improved OS in S patients only (HR:0.67, 95%CI: 0.46-0.97, p=0.03). Multivariable analysis confirmed the independent prognostic significance of LNneg histiocytes (HR:0.62, 95%CI: 0.42-0.9, p=0.01). ConclusionThese findings suggest that LN microarchitecture may be a biomarker for treatment-related immune modulation and prognosis in patients with resectable OeC. These findings warrant independent validation and further investigation to determine whether LN microarchitectural features could inform personalised therapeutic strategies.ISRCTN43987580

  • Open Access

    Clinical characteristics and outcomes of cardiomyopathies related to immune-mediated diseases

    by Valentina A Rossi, Maurits A Sikking, Alessandro Folgheraiter, Carola Pio Loco, Fernando Dominguez, Bastien S C Nihant, Sophie L V M Stroeks, Michiel T H M Henkens, Nerea Mora-Ayestarán, Noemí Ramos-López, et al.

    Aims: Dilated cardiomyopathy (DCM) encompasses genetic and acquired aetiologies, yet the impact of immune-mediated mechanisms remains unclear. This study investigates the clinical characteristics and outcomes of immune-mediated DCM (ID-CMP). Methods: From the Maastricht Cardiomyopathy registry, 194 patients with ID-CMP were compared with 678 non-immune DCM controls over a median follow-up of 5.2 (3.7–10.7) years. ID-CMP was categorized into autoimmune-mediated (adaptive immunity dysfunction), autoinflammatory-driven (innate immunity dysfunction), and mixed-pattern (MHC Class I associations and autoinflammatory components). Patients with features of >1 category were classified as overlapping-CMP. Echocardiographic and genetic data were collected. Cox regression assessed major adverse cardiovascular events (MACE: cardiac mortality, heart failure hospitalization, life-threatening arrhythmias). Left ventricular ejection fraction (LVEF) trajectories were analysed using linear mixed-effects models. Findings were validated in an independent cohort of 201 ID-CMP patients. Results: ID-CMP was associated with a higher risk of MACE [HR: 1.68 (1.1–2.5), P = .012] after adjustment for age, sex, and baseline LVEF, confirmed in an external validation cohort [HR:2.40 (1.6–3.5), P < .001]. LVEF was lower in ID-CMP during the first year but converged with non-immune DCM thereafter (P0–1year = .018; P>1year = ns). Outcomes did not differ among ID-CMP subtypes. Inflammation on EMB was related to worse clinical outcome [HR:2.0 (1.1–3.6), P = .017]. Pathogenic DCM gene variants were equally frequent in ID-CMP and non-ID-CMP patients (22% vs 20%, P = ns). Conclusion: ID-CMP patients have a higher risk of MACE despite similar LVEF trajectories, as confirmed in a validation cohort. Cardiac immune cell infiltration suggests an inflammatory substrate independent of genetics.

  • Sex Differences in Prognosis of Patients With Genetic Dilated Cardiomyopathy

    by Sophie L.V.M. Stroeks, Marco Merlo, Nerea Mora-Ayestaran, Max Jason, Upasana Tayal, Ping Wang, Antonio Cannatà, Maurits A. Sikking, Matteo Dal Ferro, Belen Peiro, et al.

    BACKGROUND: Dilated cardiomyopathy (DCM) is a genetically heterogeneous disease, presenting diverse clinical phenotypes and outcomes based on the underlying gene affected. The influence of sex on the gene-specific long-term prognosis of patients with genetic DCM remains unclear. This study aims to determine the effect of sex on the long-term prognosis per underlying genogroup. METHODS: A retrospective cohort study was conducted using data from 4 international referral centers. Baseline and longitudinal clinical data of patients with DCM, with a median follow-up of 6.7 years (interquartile range, 3.5–11.9 years), were collected. The study included men and women with DCM who had undergone genetic testing. Patients were categorized into 7 genotype groups: cytoskeletal/Z-disk, desmosomal, nuclear envelope, motor sarcomeric, TTN , other genetic, and genotype negative. The main outcomes measured were left ventricular reverse remodeling, mortality, heart failure hospitalization, heart transplantation, and malignant ventricular arrhythmias. RESULTS: Among 1716 patients, 1130 (66%) were men and 510 (30%) had a (likely) pathogenic variant. Ventricular remodeling was gene-dependent in women, with TTN patients exhibiting the highest rate ( P =0.003) and desmosomal patients the lowest ( P =0.04) compared with the genotype-negative group. After a median follow-up of 6.7 years, 334 men (29%) and 140 women (24%) reached the primary end point. Men with a (likely) pathogenic variant had the poorest prognosis, showing a higher rate of major adverse events (adjusted hazard ratio, 1.48 [95% CI, 1.12–1.95]; P =0.02) and malignant ventricular arrhythmias (adjusted hazard ratio, 1.83 [95% CI, 1.16–2.88]; P =0.009) compared with genotype-negative women. Prognosis varied by gene in men (log-rank P P =0.1). The cytoskeletal/Z-disk, desmosomal, and nuclear envelope groups had the worst prognosis in men. CONCLUSIONS: The genetic architecture and sex are critical predictors of left ventricular reverse remodeling and long-term prognosis in DCM. These factors should be integrated into individualized risk prediction models to enhance clinical outcomes in patients with DCM.


  • Open Access

    Predictive value of ambulatory ECG monitoring for malignant arrhythmic events in genetic dilated cardiomyopathy

    by Max F G H M Venner, Astrid B M Heymans, Nina J Beelen, Sophie L V M Stroeks, Isa M E Faassen, Maurits A Sikking, Michiel T H M Henkens, Saskia N van der Crabben, Anne G Raafs, Stephane R B Heymans, et al.

    Aims: Evaluate the prognostic significance of arrhythmias and conduction disorders on ambulatory ECG in recently diagnosed genetic vs. non-genetic dilated cardiomyopathy (DCM). Objective: To compare the prevalence of abnormalities on ambulatory ECG monitoring between genetic and non-genetic DCM patients and evaluate the predictive value for malignant ventricular adverse events (MVAEs). Methods and results: Clinical and ambulatory ECG data were collected from 354 genotyped DCM probands, with a median follow-up of 8 years (IQR: 5–9 years). The malignant ventricular adverse event was defined as ventricular fibrillation, sustained ventricular tachycardia, anti-tachy pacing, appropriate device therapy, or sudden cardiac death. C-statistics assessed the predictive performance of the regression models. In total, 123 (35%) patients carried a (likely) pathogenic variant. Abnormalities on ambulatory ECG were more frequent in genetic DCM patients (80%) compared to non-genetic DCM (67%; P = 0.013). Permanent atrial fibrillation (perAF), paroxysmal supraventricular tachycardia (parox-SVT), and non-sustained ventricular tachycardia (NSVT) were more frequent in genetic DCM patients (P = 0.041, <0.001, and 500 premature ventricular complexes (PVCs)/24 h) had an area under the curve (AUC) of 0.768 in genetic and 0.628 in non-genetic DCM patients (P = 0.044). The premature ventricular complex burden was only predictive for MVAE in genetic DCM. Adding clinical variables provided little incremental predictive value for genetic vs. non-genetic DCM (AUC Δ+0.004 vs. Δ+0.150, respectively). Conclusion: Ambulatory ECG monitoring abnormalities are prevalent in genetic DCM patients. In contrast to non-genetic DCM patients, ambulatory ECG parameters have an important predictive value to determine the risk of MVAE in genetic DCM patients.


  • Open Access

    The diagnostic yield of an elaborate workup for comorbidities in a real-life heart failure with preserved ejection fraction outpatient population

    by Sanne G J Mourmans, Anouk Achten, Jerremy Weerts, Marijne Scheepers, Arantxa Barandiarán Aizpurua, Michiel Henkens, Nicole Uszko-Lencer, Hans-Peter Brunner-La Rocca, Christian Knackstedt, Vanessa P M van Empel

    Aims: Comorbidities play an important role in heart failure (HF) with preserved ejection fraction (HFpEF). Still, current guidelines lack clear directives for routine comorbidity screening and are primarily based on HF with reduced ejection fraction populations. This study evaluates the diagnostic yield of standardized routine workup for comorbidities in HFpEF. The goal is to provide clinicians with actionable insights to refine strategies for screening and managing HFpEF patients. Methods and results: This single-centre prospective observational cohort study included patients diagnosed with HFpEF via a specialized outpatient clinic and evaluated the diagnostic yield of standardized diagnostic workup for comorbidities, including laboratory testing, sleep apnoea screening, 24 h Holter monitoring, spirometry, exercise testing, and 6 min walk test. A total of 501 HFpEF patients (age 75 ± 7 years, 67% female) were included. Before diagnostic workup, a median of three [2–5] comorbidities was known, and one additional comorbidity was diagnosed during standardized workup, most commonly sleep apnoea (33%) and iron deficiency (35%). Overall, the most prevalent comorbidities were hypertension (74%), sleep apnoea (52%), atrial fibrillation (50%), iron deficiency (49%), and obesity (45%). Pre-existing comorbidities did not receive optimal guideline-directed therapy, specifically diabetes (23%), hypercholesterolaemia (36%), and obesity (45%). Conclusion: This study highlights the value of routine comorbidity screening in HFpEF, identifying one new comorbidity per patient on top of three pre-existing conditions, most commonly sleep apnoea or iron deficiency. Treatment of existing comorbidities was often suboptimal. Systematic screening not only improves the detection of undiagnosed conditions but also enables personalized and effective comorbidity management.


  • Open Access

    Cytotoxic T Cells Drive Outcome in Inflammatory Dilated Cardiomyopathy

    by Maurits A. Sikking, Daniel Harding, Michiel T.H.M. Henkens, Sophie L.V.M. Stroeks, Max F.G.H.M. Venner, Bastien Nihant, Rick E.W. van Leeuwen, Silvia Fanti, Xiaofei Li, Pieter van Paassen, et al.


  • Open Access

    Quality of life and societal costs in patients with dilated cardiomyopathy

    by Isabell Wiethoff, Maurits Sikking, Silvia Evers, Andrea Gabrio, Michiel Henkens, Michelle Michels, Job Verdonschot, Stephane Heymans, Mickaël Hiligsmann

    Dilated cardiomyopathy (DCM) is a major cause of heart failure impairing patient wellbeing and imposing a substantial economic burden on society, but respective data are missing. This study aims to measure the quality of life (QoL) and societal costs of DCM patients. A cross-sectional evaluation of QoL and societal costs of DCM patients was performed through the 5-level EuroQol and the Medical Consumption Questionnaire and Productivity Cost Questionnaire, respectively. QoL was translated into numerical values (i.e. utilities). Costs were measured from a Dutch societal perspective. Final costs were extrapolated to 1 year, reported in 2022 Euros, and compared between DCM severity according to NYHA classes. A total of 550 DCM patients from the Maastricht cardiomyopathy registry were included. Mean age was 61 years, and 34% were women. Overall utility was slightly lower for DCM patients than the population mean (0.840 vs. 0.869, P = 0.225). Among EQ-5D dimensions, DCM patients scored lowest in ‘usual activities’. Total societal DCM costs were €14 843 per patient per year. Cost drivers were productivity losses (€7037) and medical costs (€4621). Patients with more symptomatic DCM (i.e. NYHA class III or IV) had significantly higher average DCM costs per year compared to less symptomatic DCM (€31 099 vs. €11 446, P < 0.001) and significantly lower utilities (0.631 vs. 0.883, P < 0.001). DCM is associated with high societal costs and reduced QoL, in particular with high DCM severity. Observational burden of disease study measuring the quality of life and societal costs in 550 patients with dilated cardiomyopathy (DCM).


  • Open Access

    Biomarkers of Collagen Metabolism Are Associated with Left Ventricular Function and Prognosis in Dilated Cardiomyopathy: A Multi-Modal Study

    by Anne G. Raafs, Bouke P. Adriaans, Michiel T. H. M. Henkens, Job A. J. Verdonschot, Myrurgia A. Abdul Hamid, Javier Díez, Christian Knackstedt, Vanessa P. M. van Empel, Hans-Peter Brunner-La Rocca, Arantxa González, et al.

    Background: Collagen cross-linking is a fundamental process in dilated cardiomyopathy (DCM) and occurs when collagen deposition exceeds degradation, leading to impaired prognosis. This study investigated the associations of collagen-metabolism biomarkers with left ventricular function and prognosis in DCM. Methods: DCM patients who underwent endomyocardial biopsy, blood sampling, and cardiac MRI were included. The primary endpoint included death, heart failure hospitalization, or life-threatening arrhythmias, with a follow-up of 6 years (5–8). Results: In total, 209 DCM patients were included (aged 54 ± 13 years, 65% male). No associations were observed between collagen volume fraction, circulating carboxy-terminal propeptide of procollagen type-I (PICP), or collagen type I carboxy-terminal telopeptide [CITP] and matrix metalloproteinase [MMP]-1 ratio and cardiac function parameters. However, CITP:MMP-1 was significantly correlated with global longitudinal strain (GLS) in the total study sample (R = −0.40, p < 0.0001; lower CITP:MMP-1 ratio was associated with impaired GLS), with even stronger correlations in patients with LVEF > 40% (R = −0.70, p < 0.0001). Forty-seven (22%) patients reached the primary endpoint. Higher MMP-1 levels were associated with a worse outcome, even after adjustment for clinical and imaging predictors (1.026, 95% CI 1.002–1.051, p = 0.037), but CITP and CITP:MMP-1 were not. Combining MMP-1 and PICP improved the goodness-of-fit (LHR36.67, p = 0.004). Conclusion: The degree of myocardial cross-linking (CITP:MMP-1) is associated with myocardial longitudinal contraction, and MMP-1 is an independent predictor of outcome in DCM patients.


  • Open Access

    Clonal Hematopoiesis of Indeterminate Potential From a Heart Failure Specialist's Point of View

    by Maurits A. Sikking, Sophie L. V. M. Stroeks, Olivia J. Waring, Michiel T. H. M. Henkens, Niels P. Riksen, Alexander Hoischen, Stephane R. B. Heymans, Job A. J. Verdonschot

    Clonal hematopoiesis of indeterminate potential (CHIP) is a common bone marrow abnormality induced by age‐related DNA mutations, which give rise to proinflammatory immune cells. These immune cells exacerbate atherosclerotic cardiovascular disease and may induce or accelerate heart failure. The mechanisms involved are complex but point toward a central role for proinflammatory macrophages and an inflammasome‐dependent immune response (IL‐1 [interleukin‐1] and IL‐6 [interleukin‐6]) in the atherosclerotic plaque or directly in the myocardium. Intracardiac inflammation may decrease cardiac function and induce cardiac fibrosis, even in the absence of atherosclerotic cardiovascular disease. The pathophysiology and consequences of CHIP may differ among implicated genes as well as subgroups of patients with heart failure, based on cause (ischemic versus nonischemic) and ejection fraction (reduced ejection fraction versus preserved ejection fraction). Evidence is accumulating that CHIP is associated with cardiovascular mortality in ischemic and nonischemic heart failure with reduced ejection fraction and involved in the development of heart failure with preserved ejection fraction. CHIP and corresponding inflammatory pathways provide a highly potent therapeutic target. Randomized controlled trials in patients with well‐phenotyped heart failure, where readily available anti‐inflammatory therapies are used to intervene with clonal hematopoiesis, may pave the way for a new area of heart failure treatment. The first clinical trials that target CHIP are already registered.